Compare ARQQ & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | ELDN |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United Kingdom | United States |
| Employees | 91 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 300.4M |
| IPO Year | N/A | 2014 |
| Metric | ARQQ | ELDN |
|---|---|---|
| Price | $14.51 | $3.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $60.00 | $8.50 |
| AVG Volume (30 Days) | 344.4K | ★ 1.7M |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $381.13 | N/A |
| Revenue Next Year | $212.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.52 | $1.35 |
| 52 Week High | $62.00 | $4.60 |
| Indicator | ARQQ | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 54.94 |
| Support Level | $11.72 | $2.50 |
| Resistance Level | $17.75 | $3.51 |
| Average True Range (ATR) | 1.20 | 0.26 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 45.72 | 36.84 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.